Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile

Lupin receives European Commission approval for biosimilar Ranibizumab

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences

40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions

Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe

This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway

GenSight Biologics gets early access nod for candidate gene therapy in Israel

Applications include detailed scientific rationale and supporting clinical evidence

Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan

The partnership also sets the stage for broader collaboration on rare disease treatments

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A